SCHEMBL28909787

SCHEMBL28909787

CN(CCCCCCN)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.42
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CA14 Q9ULX7 1/20 0.39
PAOX Q6QHF9 3/20 0.35
CTSK P43235 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 2/20 0.35
ACHE P22303 1/20 0.33
PDK2 Q15119 1/20 0.33
CPB2 Q96IY4 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PLG P00747 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
SLC6A2 P23975 1/20 0.32
RECQL P46063 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22291496 1.00 CHRM2 (0.42) CHRM2HDAC1HDAC2HDAC6CA14
SCHEMBL2722798 1.00 CHRM2 (0.42) CHRM2HDAC1HDAC2HDAC6CA14
SCHEMBL18391125 1.00 CHRM2 (0.42) CHRM2HDAC1HDAC2HDAC6CA14
SCHEMBL1654128 0.98 CA14 (0.40) CHRM2HDAC1HDAC2HDAC6CA14
SCHEMBL55404 0.93 HDAC6 (0.38) CHRM2HDAC1HDAC2HDAC6CA14
SCHEMBL17770771 0.92 CA14 (0.49) CHRM2HDAC1HDAC2HDAC6CA14
Hydrochloric Acid SCHEMBL28028259 0.91 HDAC6 (0.37) CHRM2HDAC1HDAC2HDAC6CA14
SCHEMBL15284921 0.89 CA14 (0.40) HDAC6CA14PAOXCTSKLMNA
SCHEMBL23728825 0.86 CHRM2 (0.39) CHRM2HDAC1HDAC2HDAC6CA14
SCHEMBL25720861 0.85 ALDH1A1 (0.42) CHRM2HDAC1HDAC2HDAC6CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167105-A1 BCL-2 PROTEIN INHIBITORS RECURIUM IP HOLDINGS, LLC 2023-06-01 US disclosed
EP-4107152-A1 BCL-2 PROTEIN INHIBITORS Recurium IP Holdings, LLC (US) 2022-12-28 EP disclosed
CN-115461335-A BCL-2 protein inhibitors 里科瑞尔姆IP控股有限责任公司 2022-12-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167105-A1 BCL-2 PROTEIN INHIBITORS BCL2, BCL2L1, BCL2L2 CHRM2 4881/4885HDAC1 409/4885HDAC2 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.